Beijing Qihuang Pharmaceutical

Beijing Qihuang Pharmaceutical is a clinical-stage biotechnology company based in China, specializing in the development of innovative small molecule therapies for metabolic and endocrine disorders. The company's primary focus is on the discovery and advancement of multi-receptor agonists targeting GLP-1, GCG, and GIP pathways to treat conditions such as type 2 diabetes and obesity. Their lead candidate, QH-5828, is an orally available small molecule GLP-1 receptor agonist currently undergoing clinical evaluation. By leveraging expertise in medicinal chemistry, the company aims to provide more convenient and effective oral alternatives to existing injectable peptide therapies. Beijing Qihuang Pharmaceutical continues to expand its pipeline to address significant unmet needs in the metabolic disease space.